Literature DB >> 11418688

Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells.

S J Lee1, Y S Cho, M C Cho, J H Shim, K A Lee, K K Ko, Y K Choe, S N Park, T Hoshino, S Kim, C A Dinarello, D Y Yoon.   

Abstract

Cervical carcinoma is the predominant cancer among malignancies in women throughout the world, and human papillomavirus (HPV) 16 is the most common agent linked to human cervical carcinoma. The present study was performed to investigate the mechanisms of immune escape in HPV-induced cervical cancer cells. The presence of HPV oncoproteins E6 and E7 in the extracellular fluids of HPV-containing cervical cancer cell lines SiHa and CaSki was demonstrated by ELISA. The effect of HPV 16 oncoproteins E6 and E7 on the production of IFN-gamma by IL-18 was assessed. E6 and E7 proteins reduced IL-18-induced IFN-gamma production in both primary PBMCs and the NK0 cell line. FACS analysis revealed that the viral oncoproteins reduced the binding of IL-18 to its cellular surface receptors on NK0 cells, whereas there was no effect of oncoproteins on IL-1 binding to its surface IL-1 receptors on D10S, a subclone of the murine Th cell D10.G4.1. In vitro pull-down assays also revealed that the viral oncoproteins and IL-18 bound to IL-18R alpha-chain competitively. These results suggest that the extracellular HPV 16 E6 and E7 proteins may inhibit IL-18-induced IFN-gamma production locally in HPV lesions through inhibition of IL-18 binding to its alpha-chain receptor. Down-modulation of IL-18-induced immune responses by HPV oncoproteins may contribute to viral pathogenesis or carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418688     DOI: 10.4049/jimmunol.167.1.497

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene.

Authors:  Sojung Lee; Jung-Hee Kim; Heejong Kim; Jeong Woo Kang; Soo-Hyun Kim; Young Yang; Jinman Kim; JongSup Park; SurNie Park; JinTae Hong; Do-Young Yoon
Journal:  Immunology       Date:  2011-01-05       Impact factor: 7.397

2.  Genetic dysregulation in recurrent respiratory papillomatosis.

Authors:  Regina Rodman; Simukayi Mutasa; Crystal Dupuis; Heidi Spratt; Michael Underbrink
Journal:  Laryngoscope       Date:  2014-03-11       Impact factor: 3.325

3.  Decreased local immune response and retained HPV gene expression during chemoradiotherapy are associated with treatment resistance and death from cervical cancer.

Authors:  Pippa F Cosper; Christopher McNair; Iván González; Nathan Wong; Karen E Knudsen; Jason J Chen; Stephanie Markovina; Julie K Schwarz; Perry W Grigsby; Xiaowei Wang
Journal:  Int J Cancer       Date:  2019-12-04       Impact factor: 7.396

Review 4.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

Review 5.  Immune therapy for human papillomaviruses-related cancers.

Authors:  Ricardo Rosales; Carlos Rosales
Journal:  World J Clin Oncol       Date:  2014-12-10

6.  Sensitization of cervix cancer cells to Adriamycin by Pentoxifylline induces an increase in apoptosis and decrease senescence.

Authors:  Alejandro Bravo-Cuellar; Pablo C Ortiz-Lazareno; Jose M Lerma-Diaz; Jorge R Dominguez-Rodriguez; Luis F Jave-Suarez; Adriana Aguilar-Lemarroy; Susana del Toro-Arreola; Ruth de Celis-Carrillo; Jose E Sahagun-Flores; Javier E Garcia de Alba-Garcia; Georgina Hernandez-Flores
Journal:  Mol Cancer       Date:  2010-05-19       Impact factor: 27.401

7.  Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity.

Authors:  Patrick C Reading; Geoffrey L Smith
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model.

Authors:  Tai-Gyu Kim; Chang-Hyun Kim; Eun Ha Won; Su Mi Bae; Woong-Shick Ahn; Jae-Bok Park; Jeong-Im Sin
Journal:  Immunology       Date:  2004-05       Impact factor: 7.397

9.  Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions.

Authors:  Trinidad Garcia-Iglesias; Alicia Del Toro-Arreola; Benibelks Albarran-Somoza; Susana Del Toro-Arreola; Pedro E Sanchez-Hernandez; Maria Guadalupe Ramirez-Dueñas; Luz Ma Adriana Balderas-Peña; Alejandro Bravo-Cuellar; Pablo C Ortiz-Lazareno; Adrian Daneri-Navarro
Journal:  BMC Cancer       Date:  2009-06-16       Impact factor: 4.430

10.  Therapeutic vaccines against human papillomavirus and cervical cancer.

Authors:  Angel Cid-Arregui
Journal:  Open Virol J       Date:  2009-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.